firstly that would be very illegal to sabotage a product and no way BP would take such a risk.
furthermore, Avelumab is a sparsely used treatment compared to other drugs available. BP wants good results from this trial, they are probably desperate for Avelumab to be prescribed on a larger scale. They are hoping that Hervaxx will increase effectiveness of Avelumab.
Either way, this is fantastic for Imugene, I have no doubt that other combinations and collaborations are being discussed and at this stage Imugene is saying thanks but no thanks.. for now, but keep your chequebooks open because the best is yet to come.
To me it looks like Imugene is very carefully selecting where and how to allow BP in. This is just the first of some huge opportunities to come.
- Forums
- ASX - By Stock
- IMU
- Ann: Clinical Trial Supply Agreement with Merck KGaA and Pfizer
Ann: Clinical Trial Supply Agreement with Merck KGaA and Pfizer, page-187
-
- There are more pages in this discussion • 66 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMU (ASX) to my watchlist
(20min delay)
|
|||||
Last
5.7¢ |
Change
-0.002(3.39%) |
Mkt cap ! $418.9M |
Open | High | Low | Value | Volume |
6.0¢ | 6.2¢ | 5.6¢ | $1.863M | 31.44M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 515002 | 5.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.8¢ | 60000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 40141 | 0.060 |
1 | 309971 | 0.059 |
3 | 120114 | 0.058 |
5 | 351000 | 0.057 |
17 | 1804259 | 0.056 |
Price($) | Vol. | No. |
---|---|---|
0.052 | 320450 | 13 |
0.054 | 108987 | 3 |
0.055 | 40800 | 3 |
0.058 | 60000 | 1 |
0.059 | 959109 | 7 |
Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
Featured News
IMU (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online